Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  OTC Bulletin Board  >  IntelGenx Technologies Corp.    IGX

 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2016 6,19 M
EBIT 2016 0,39 M
Net income 2016 0,25 M
Debt 2016 -
Yield 2016 -
Sales 2017 5,33 M
EBIT 2017 -1,25 M
Net income 2017 -1,34 M
Debt 2017 -
Yield 2017 -
P/E ratio 2016 161,01
P/E ratio 2017
Capi. / Sales2016 8,28x
Capi. / Sales2017 9,61x
Capitalization 51,2 M
More Financials
Company
IntelGenx Technologies Corp. operates as a drug delivery company.It focuses on the development of novel, orally administered drug delivery products based on its proprietary oral drug delivery technologies.The company is a provider of product development services for the pharmaceutical industry,... 
Sector
Pharmaceuticals
Calendar
11/09Earnings Release
More about the company
Surperformance© ratings of IntelGenx Technologies Cor
Trading Rating : - Investor Rating :
More Ratings
Latest news on INTELGENX TECHNOLOGIES COR
09/21 INTELGENX TECHNOLOGIES CORP. : Other Events (form 8-K)
09/21 INTELGENX TECHNOLOGIES : and RedHill Biopharma Announce RIZAPORT(R) Commercializ..
09/16 INTELGENX TECHNOLOGIES : Grants Stock Options
09/16 INTELGENX TECHNOLOGIES : Grants Stock Options
09/15 INTELGENX TECHNOLOGIES : Announces development and commercialization agreement f..
09/12 INTELGENX TECHNOLOGIES CORP. : Other Events (form 8-K)
09/12 INTELGENX TECHNOLOGIES : Announces Development and Commercialization Agreement f..
09/07 INTELGENX TECHNOLOGIES : to Present at the 18th Annual Rodman & Renshaw Global I..
08/22 INTELGENX TECHNOLOGIES CORP. : Other Events (form 8-K)
08/22 INTELGENX TECHNOLOGIES : Announces Successful Clinical Study for Montelukast for..
More news
Sector news : Generic Pharmaceuticals
05:36pDJPFIZER : Throws Out Plan to Split Into Two Companies -- 2nd Update
05:36pDJMYLAN : Clarifies EpiPen Profit Figures it Provided to Congress Last Week
04:45pDJPFIZER : Won't Pursue a Split of Established and New Medical Lines
01:53pDJPFIZER : Won't Pursue a Split of Established and New Medical Lines -- Update
07:49aDJSANOFI : FDA Accepts Sanofi's, Regeneron's Dermatitis Treatment for Priority Rev..
More sector news : Generic Pharmaceuticals
Advertisement
Income Statement Evolution
More Financials
Consensus 
Mean consensus BUY
Number of Analysts 1
Average target price 1,50 $
Spread / Average Target 86%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Horst G. Zerbe Chairman, President & Chief Executive Officer
André Godin Chief Financial Officer & Executive Vice President
Nadine Paiement Director-Research & Development
Bernd Josef Melchers Independent Director
John Archibald Troup Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
INTELGENX TECHNOLOGIES..51
SUN PHARMACEUTICAL IND..-5.02%28 165
OTSUKA HOLDINGS CO LTD5.19%25 163
BIOMARIN PHARMACEUTICA..-7.03%16 634
ONO PHARMACEUTICAL CO...-37.03%15 857
ASPEN PHARMACARE HOLDI..5.62%10 757
More Results